-
Aug 03, 2022
Late last week, Senate Majority Leader Chuck Schumer (D-NY) and Senator Joe Manchin (D-WV) announced they reached an agreement on an expanded Build Back Better/reconciliation bill. See Inflation Reduction Act of 2022 – Text and Summaries. While the situation remains fluid, now is a good time to explain key points and timing of this major development/breakthrough.
Full story
-
Jul 15, 2022
Updates on two developing issues at the federal and state levels: FDA Includes Pharmacists in Revised Paxlovid Prescribing Authority, and Florida is Re-evaluating State PBM Contracts
Full story
-
Jul 12, 2022
Full story
-
Jun 10, 2022
On June 7, the Federal Trade Commission (FTC) announced that it will begin an inquiry into PBM practices – particularly the actions of the 6 largest PBMs (CVS Caremark, Express Scripts (ESI), Optum, Humana, Prime, & MedImpact).
Full story
-
Jun 08, 2022
Jenni Zilka, SVP, Community & Specialty Pharmacy and President, Good Neighbor Pharmacy and Kevin Ban, Chief Medical Officer, Walgreens, have co-authored an article that urges the passage of H.R. 7213, the Equitable Community Access to Pharmacist Services Act, bipartisan federal legislation that enables patients to continue to receive treatment from pharmacists for pandemic-related and respiratory health conditions.
Full story
-
Jun 02, 2022
AmerisourceBergen is a member of the Alliance to Modernize Prescribing Information (AMPI) – a group of pharmaceutical stakeholders with a common interest in advancing regulatory or legislative reforms to facilitate the dissemination of FDA-approved pharmaceutical labeling information via modern digital platforms. For more information on the issue, please visit AMPI’s website.
Full story
-
May 27, 2022
On May 24th, U.S. Senators Maria Cantwell (D-WA), Chair of the Senate Committee on Commerce, Science, and Transportation, and Chuck Grassley (R-IA), Ranking Member of the Senate Judiciary Committee, introduced the Pharmacy Benefit Manager Transparency Act of 2022, which would empower the Federal Trade Commission (FTC) to increase drug pricing transparency and hold PBMs in both commercial and government sponsored/funded plans accountable for “unfair and deceptive practices that drive up the costs of prescription drugs at the expense of consumers.”
Full story
-
May 16, 2022
On May 5, the U.S. Senate Commerce, Science and Transportation Committee’s Subcommittee on Consumer Protection, Product Safety, and Data Security held a hearing titled, “Ensuring Fairness and Transparency in the Market for Prescription Drugs,” which “examine[d] steps Congress can take to increase transparency in drug prices, require PBMs to operate fairly, and ensure the FTC has the authority it needs to stop unfair practices in the prescription drug market.”
Full story
-
May 03, 2022
CMS issued its Final Medicare Advantage and Part D rule, which includes changes to Part D plan contracting with pharmacies – though Part D contracts will not reflect the changes until CY 2024. The good news is that CMS’ action lays out the details of a concrete, significant step in DIR fees-related reform for which AmerisourceBergen, Good Neighbor Pharmacy, Elevate Provider Network, and the pharmacy, physician and pharmaceutical industry has advocated for several years.
Full story
-
Apr 25, 2022
Urge your U.S. Representative to cosponsor a new, bipartisan bill to provide established Medicare Part B recognition and direct reimbursement for pharmacist services related to the COVID-19 pandemic and other illnesses.
Full story